Skip to main content
Equibles
CRMD logo

CRMD · CorMedix Inc. · Metrics

Track CRMD — free

Use CRMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.70 +0.13 (+1.72%)
Russell 2000 member Rebalance outlook locked
Market Cap
$590.04M
Shares
77.94M
Volume · Oct 20 971.71K Avg daily vol (3M) 1.12M

CRMD metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.57
Market cap
$590.04M

Price action

20 metrics
Price change (1W)
+2.4%
Price change (30D)
-2.6%
Price change (3M)
-7.6%
Price change (6M)
+2.6%
Price change (YTD)
-34.9%
Price change (1Y)
-37.7%
Trailing year
Price change (5Y)
+59.0%
52-week high
$12.73
52-week low
$6.25
Change from 52-week high
-40.5%
Change from 52-week low
+21.1%
Annualized volatility
57.8%
Annualized volatility (3M)
47.2%
Beta
1.1
RSI (14D)
50.0
Price vs SMA 50
-3.3%
Price vs SMA 200
-2.0%
Avg volume (3M)
1.12M
Relative volume
0.9
Average dollar volume
$8.70M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
77.94M

Valuation

12 metrics
P / E (TTM)
3.5
Trailing earnings · reciprocal yield 28.8%
PEG ratio
1.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 78.3%
P / book
1.3
reciprocal yield 78.1%
FCF yield
42.4%
TTM · current market cap
Buyback yield
—
P / FCF
2.4
reciprocal yield 42.4%
P / operating cash flow
2.3
reciprocal yield 43.0%
Earnings yield
31.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1,472.5×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
1,079.5×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
82.8%
Operating margin
47.0%
Trailing 12 months
Net margin
40.5%
Gross profit (TTM)
$382.64M
Operating profit (TTM)
$217.04M
Net income (TTM)
$187.17M
Trailing 12 months
Diluted EPS (TTM)
$2.18
FCF margin
54.2%
Effective tax rate
8.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.11

Growth

11 metrics
Revenue growth YoY
+156.5%
Year over year
Net income growth YoY
+31.1%
Revenue (TTM)
$462.25M
Trailing 12 months
EPS growth YoY
+3.6%
Shares change YoY
+28.6%
Year over year · more shares
Revenue CAGR (3Y)
+1,582.8%
Revenue CAGR (5Y)
+319.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
40.6%
Return on assets
20.7%
Debt / equity
—
Current ratio
2.6
EBITDA (TTM)
—
Free cash flow (TTM)
$250.42M
Quick ratio
2.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$256.69M
Latest balance sheet
Cash & equivalents
$256.69M
Total assets
$904.05M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$253.94M
Capital expenditures (TTM)
$3.52M
R&D (TTM)
$27.59M
SG&A (TTM)
$43.24M
Stock compensation (TTM)
$16.32M
R&D / revenue
6.0%
Stock compensation / revenue
3.5%

Ownership (13F)

9 metrics
13F filers
196
13F filer change QoQ
+3
Institutional ownership
58.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
14.0%
Private-fund adviser ownership
11.8%
Active holders' share change QoQ
+9.4%
Holder tenure
9.3
Price vs estimated holder cost
-15.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.8%

Short interest

3 metrics
Short interest
19.8%
Latest settlement · 18.9 days to cover
Days to cover
18.9d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1410098 CUSIP 21900C308 13F (30d) 13 filings 13 filers Visit website Investor relations